Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.71 USD | +1.35% | +1.49% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15M | Capitalization | 395M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 204M | Net cash position 2025 * | 59.74M | EV / Sales 2025 * | 22.3 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.49% |
1 day | +1.35% | ||
1 week | +1.49% | ||
Current month | +0.71% | ||
1 month | +1.88% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 15.71 | +1.35% | 50,676 |
24-05-17 | 15.5 | +3.61% | 63,002 |
24-05-16 | 14.96 | -2.29% | 26,279 |
24-05-15 | 15.31 | -0.97% | 28,648 |
24-05-14 | 15.46 | -0.13% | 34,028 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 395M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.62% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- CTNM Stock